and the HIV/AIDS Research Ethics Board at the University of Toronto [28859] . Given the cultural complexity of research in South Africa, and to ensure that the values and interests of key stakeholders were taken into account, we partnered locally with site-staff at a South African trial site. Community partners, such as CAB members, were instrumental in guiding the initial exploratory stage of the research. Meetings and workshops were conducted to obtain feedback and suggestions to ensure the relevance and sensitivity of the study. Written informed consent was also obtained for participation in the FGDs following the presentation and discussion of our study with potential study participants (cf. Emanuel et al., 2004) .
Data Analysis:
The data analysis process was conducted by three of the authors. Focus groups were transcribed, and all names and identifying details redacted. The physical material produced through the brainstorming process was also textually represented. The software program NVivo (QSR International) was used to organise and analyse the data. An 'NVivo project' -a filing and analytic system in the software program within which project documents and codes were organised -was developed around key themes and ideas that emerged during the data collection process. Thematic analysis (Boyatzis, 1998; Braun & Clarke, 2006) was then employed to identify conceptions of key trial concepts, with a particular focus on 'competing versions' in the data. The constant comparative method was also used alongside multiple forms of coding (Miles & Huberman, 1994) in order to uncover manifest and latent themes and patterns in the focus group narratives. This included line-by-line coding with the identification of participants' own language and wording of key concepts. Each researcher initially independently coded the data, followed by collaborative workshops in which codes were compared, discrepancies resolved, and coding frameworks standardised. In order to systematically identify and explore 'competing versions' in the data, they were operationalised as: (1) the concern of a FGD participant in a single utterance or sequence of talk; (2) an interactional concern that emerged between two or more FGD participants or (3) various competing models -both implicit and explicitidentified or interpreted by the research team during the data analysis process.
In order to enhance the credibility and trustworthiness of the findings, member checks were conducted with many of the respondents (Babbie & Mouton, 2005) . The main findings and interpretations presented in the present paper were shared with the respondents -and other trial site staff -at various feedback meetings hosted by the researchers at the site. The respondents were invited to critically engage with the results presented in the present paper, and, consequently, affirmed that the findings were accurate representations of their views.
RESULTS
Our broad study aimed to explore lay and indigenous representations of research and vaccine concepts, and their implications for enhancing the consent process. A sub-set of results -presented here -relate to a plethora of mental models and representations of trials and key role players or stakeholders. As the findings emerged, one of the most striking features of the data was the diverse and competing nature of these representations. This paper presents findings related to these various and conflicting models (representations) of research and research stakeholders volunteered by FGD participants, and their relevance for the consent process and related activities such as stakeholder engagement. Findings related to specific concepts such as VISP as well as findings related to interpersonal factors such as trust, are set out in another paper (Rautenbach et al., under preparation) . In the section that follows we explore competing representations of key concepts (e.g. VISP) as well as representations of key trial stakeholders (CABS, trial participants, communities from which participants are drawn).
HVT-related Concepts
One of the most striking examples of competing versions of HIV vaccine trials emerged in relation to HIV vaccines and VISP. In each of the findings reported below the sources of the competing versions (for example, communities or CABs) are identified.
Vaccines:
Our respondents revealed that HIV vaccines were occasionally positively (but inaccurately) represented by community members as "the cure" where "most people they confuse it, they think it's the cure medicine" (FGD 1, CAB). Community members were also represented as having 'preventive misconceptions': "If I talk about in a vaccine, they think that 'oh meaning if I'm vaccinated, no need to use a condom at all, no need to use contraceptive, at all, cos, I will I will be safe, with HIV I will be safe with pregnancy I will be safe" (FGD 3, Outreach Workers). Community members were also identified as perceiving vaccines as HIVcausing: "Because you gonna get the HIV vaccine and then they think 'oh maybe I will, I might be infected they might inject you, inject me with HIV' (FGD 3, Outreach workers).
Our respondents reported that representations of vaccines varied across communities, so that "one would have an understanding about the vaccine, one community would have, no understanding" (FGD 3, Outreach Workers). Respondents suggested that some communities "do know about the vaccines that are available, and they do even know the word vaccine what does it mean" (FGD 3, Outreach Workers). For example, non-experimental vaccines such as those for polio and tuberculosis were represented as familiar and having credibility. However, when specifically referring to experimental HIV vaccines, the community was represented as having "no idea or they haven't heard of [them] before" (FGD 3, Outreach Workers). Respondents suggested that some of "the clinics do not have an idea of HIV research, do not have an idea of vaccine" (FGD 4, Counsellors).
Vaccine-Induced Seropositivity (VISP):
VISP was reported to be a confusing concept for many stakeholders. The respondents provided a clear sense of this confusion by referencing the common paradoxical statement reportedly made by trial participants -"I'm positive, but I'm negative" (FGD 1, CAB). The data reveal distinct competing representations of VISP, as exemplified in the extract below:
There are some participants that are participating in our, in our, vaccine um, trials. So when they go out they tell, the family or the community that, I'm doing a study there, a vaccine trial, so, there they told me that I must not um, go and, test in a clinic because they will, think that I'm HIV positive maybe my result has come out HIV positive although I know that I am not HIV positive. It's because of the, of the vaccine that I did get. So the people get shocked, 'What?! Because when you go to the clinic they are going to see that you are HIV positive? How does that happen?' So the person can't, explain to them, [P: explain to them yes] so that, they take that information that, if you go to that centre, they will infect you with HIV (FGD 3, Outreach Workers).
Firstly, as the above extract reveals, some participants and community members reportedly understood the conception of VISP communicated by trials -that VISP is a function of HIV vaccine-administration and to avoid social harms participants should only do HIV testing at sites that are resourced to test using algorithms that exclude VISP. In contrast the extract also points to the way in which some community members reportedly saw VISP as evidence that trial sites deliberately infect participants with HIV: "Another myth is that we infect people with HIV. That centre infects people with HIV. We can't, we can't go there because, when they get those, vaccines, then, it it is about this uh, concept, the VISP. So that's the other myth that we find it a challenge" (FGD 3, Outreach Workers). Secondly, the extract illustrates how some roleplayers (such as clinic staff in primary healthcare facilities) reportedly see VISP as an impossible and illusory phenomenon. In one such instance, a participant allegedly attempted to explain her HIV positive rapid test result as a function of VISP, however "they didn't believe her…she was lying, she was in denial that she is HIV positive, she was in denial there is no such thing" (FGD 4, Counsellors). These latter understandings of VISP may complicate how trial information is understood or accepted by potential participants. It is also possible that an accurate understanding of the risks and burdens posed by VISP (e.g., being disbelieved by clinic staff, the consequences of false-positive tests on work or insurance) may cause some potential participants to choose not to enrol.
Research Stakeholders
Trial participants: A key and common representation of trial participants was that of the 'hero' in the collective struggle against HIV:
You take part on research, um, it means you, you are part of a history-making. So that they feel as well that, they, not just being there, to, so that you try things to them. But they also they part of, something that will happen, for their children, for the generation to come that-so now when you when you do that to them, you make um them belong, you make them that you also wanna make change you also wanna make history. (FGD 2, CAB) .
This representation draws on familiar anti-apartheid discourse that emerged during the struggle against white racial domination in South Africa, and appeared to be utilized by CABs to mobilise communities to engage in HIV vaccine trials. Here the trial participant was positioned as a hero in the nation-wide struggle against HIV, and whose contribution would positively impact future generations. Positive representations such as these served to invite community members to come forward for participation, as well as to affirm current trial participants. Trial participants were represented as heroic sacrificers -who endure risks and burdens -as set out by one CAB member who remarked "We don't go to the communities and lie that this will bring heaven and earth. It's like milk and honey. We go to communities and say, 'it will be painful.' (FGD 2, CAB) . Respondents also drew upon sacrifice and risks to describe the fatigue associated with participation thus positioning participants in an ostensibly unheroic way.
A representation of participants that seemed opposed to their position as heroes was that of trial participants as complex and 'untrustworthy' -misrepresenting to site-staff their condom use, their adherence to protocols, or their desire to withdraw and providing conflicting information to various site-staff and misrepresenting to the community their experience of trials. For example, as one outreach worker stated, "You can see by stories or games that they are playing that they are not interested" (FGD 3, Outreach Workers) . Participants were also constructed as "guinea pigs" in trials -"commonly people say we make them guinea, guinea pigs" (FGD 2, CAB).
These are so very difficult because where we coming from post, 1994 elections. And if you know remember during the time of the apartheid our people were being taken to, be, guinea pigs. So for us now to come with the concept of the research or, it was very difficult (FGD 2, CAB)
The extract below exemplifies an instance of a contest between the community (who position trial participants as guinea pigs) and a CAB member, who is also an actual trial participant (who opposes this representation):
And when I reach out to the community I explain to them that I am also, one of those participants on the site, so I practice what I actually preach to them. So (doing that), something's easier for them to understand that, I don't feel, guinea-piggy. Uh because I I uh me, being called guinea pigs, so so I don't I feel free, to explain to them because they will be questioning me, whether, 'have you ever been tested, or have you ever, participated yourself, so how do you want me now to actually, go and, participate on this uh these studies. D'you want me to, be a guinea pig only and you will be staying aside? Then I say no, I've been I've gone through this my own self, so, I practice what I actually preach so it's, th-u::h, I'm trying to actually build, an HIV-free society. Huh? That's what actually my practice is. (FGD 2, CAB) Representations of trial participants as guinea pigs may well be rooted in historical abuses under Apartheid and are likely to deter community members from seeking more information about trials: Depending on which representation (guinea pig or hero) is endorsed may lead to different outcomes in decision-making about whether to seek further information about trials, or to decide to take part in one.
Research site:
Our respondents reported several positive representations of the site. For example, participants noted that "to come to a research site, it's most welcomed clinic, than in a public hospital. You will get uh, soft drink, and then you will be welcomed, and then you will be served, as early as, possible. You won't sit here for the whole day". Further, the site was constructed as providing 'good service' and if participants tested positive for HIV they would be "properly referred". (FGD 2, CAB). In contrast to expensive private health care (including traditional African medicine) and inefficient public facilities, "when you come to the site, you can just come and say I need to make an appointment with so-and-so, so that the person can see me" (FGD 2, CAB). This suggests that ancillary-care responses implemented for screening and enrolled participants are positively characterized by these trial stakeholders. On the other hand, our respondents reported that there were numerous negative representations of the site as mysterious, untrustworthy and possibly dangerous, because community members had "no idea what is happening here" and that "people here are being given things, that there's not even known what it's going to do to them..." (FGD 4, Counsellors) . Our respondents reported a common assumption amongst community members that "if you go to that building [the site], you are HIV positive" (FGD 3, Outreach workers) or "you are given HIV here" (FGD 4, Counsellors) and "if you go to that centre, they will infect you with HIV" (FGD 3, Outreach Workers). These competing representations of the site will have to be negotiated by potential participants with outreach staff during outreach activities (possibly impacting on whether potential participants will approach sites) as well as with consent staff during consent activities (possibly impacting on whether trial information will be accepted as true).
Research/ers: Characterizations of researchers by community members were reportedly predominantly suspicious. For example, researchers were viewed as 'brainwashing' the community and trial participants ('they're just playing our minds'), or as suspect persons seeking to exploit communities. Representations of exploitative researchers were often overtly racialised, with poor, vulnerable 'black people' positioned as potential victims of cunning 'white' researchers, who could, for example, 'sell our blood'. However, our respondents frequently contested such negative representations. Researchers were also represented as 'foreign' -with one CAB member even suggesting that there was a need to "bring the scientist closer to the people…not something very easy" (FGD 2, CAB).
All of our respondents recognised, understood and supported the research enterprise, characterising it as beneficial and even "history-making" (FGD 2, CAB). However, community members reportedly had low levels of research literacy -"the concept of, uh trials and research in communities is still something that people, um, don't we-don't really know well." (FGD 1, CAB). Research was viewed by community members as potentially 'dangerous' and 'risky': "I am told my risks of being in the study, I would be sssscared maybe you know, because I would be told maybe I will get sick" (FGD 1, CAB) . Community expectations that research should yield short-term benefits were also reported. To counter these views, CAB members and Vaccine Educators appealed to familiar and credible medicines and vaccinessuch as ARVs and the polio vaccine -in order to demonstrate the long-term benefits of research.
if you tell them that, each and every medication even the Grandpa, the Panado that you are taking when you've got an headache, it's coming from the research it just it it didn't just exist. [P: mm] It was researched and then, it was clinical trialed (…) Then they do understand. That on the long run then 'this is what I'm going to benefit. (FGD 4, Counsellors) CABs and Vaccine Educators also appealed to the cultural notion of 'Ubuntu' in order to motivate community members to get involved in trials, and to justify potential risks for long-term benefit. "Where people understand that, it might kill me it might kick me it might make me (suffer), but at some point, somebody, in the near future, will benefit. So, so, ubuntu has played a major role." (FGD 2, CAB) .
The key trial component of confidentiality was also reportedly understood by community members in a suspicious light (even while our respondents recognised confidentiality as a critical protection). -"when you go to communities or our societies when you talk about things that are confidential, they raise eyebrows" (FGD 1, CAB) .
P7: That's when people want to pull from things. Because they're it's confidentiality, why is there this confidentiality? It seems that, serious the site is killing the people. R2: hmh  ((some laughter) ) R1: Can I just check, ((name)) are you saying, that people are saying that's  why you want to keep it confidential, [P7: ja because] because the sites are killing people and you don't want anybody to know ((laughter)) P7: It's not a joke P5/6?:It's the way they believe R2: And how, how do they think the site is killing people? P7: By injecting them. R2: And keeping them there? P7: Keeping them confidential (FGD 1, CAB)
In the above extract confidentiality is represented by community members as a concealment device for purportedly unethical activities. The respondents' laughter, however, demonstrates that CAB members contest this view.
These findings about representations of research(ers) indicate that information about trials (their aims, procedures, risks and benefits) is not likely to be uncritically taken up by community members or potential participants, because this information competes with more suspicious conceptions. Engagement and consent staff are at the forefront of encountering and countering such views. Potential participants are likely to be positioned between these conflicting views, which makes decision-making about trials more complex and possibly stressful.
Participating community: Representations of community were the most strikingly conflicted. There was a sense from the data that "clinical trials is something new to them", and "they a bit difficult to understand why these clinical trials are done on them, like on human beings" (FGD 4, Counsellors) . The community was represented as being somewhat 'suspicious' of trials. One way in which our respondents accounted for this was by characterising the community as one which "grew up in a society whereby majority of our people believe in traditional medicines" (FGD 1, CAB) . However, the community was also represented as the source of myths and misinformation about trials and the site, so that suspicion and 'ignorance' (FGD 3, Outreach Workers) was explained by "the rumours, you know because they, people, it's about people that they don't have information, correct information" (FGD 3, Outreach Workers). Community members were characterized as lacking education -"let's face it -where we come from, we are not, the education level is not the same" (FGD 1, CAB).
In contrast, community members were also represented as intelligent and testing "…they do have difficult questions where they are very smart…" (FGD 4, Counsellors) and "people (…) will challenge you until you don't want to go back there" (FGD 2, CAB) . Rather than being suspicious, the community was also represented as inquisitive, "very very very interested" in HVTs (FGD 3, Outreach Workers) and even "eager to join the studies" (FGD 4, Counsellors) . Participating communities were represented as embodying the principles of 'ubuntu' (FGD 2, CAB) and as 'heroes' in the struggle against HIV. As a trial site staff member says of trial participants drawn from the local community, they were also characterized as 'trusting' of demographically-matched groups of site staff:
I think the participants trust that, the people that they are here are the same as them like, I'm black, and then they are black. They trust that they are gonna give them, the correct information when we explain the informed consent. Because if we explain the, if we explain in their language and then they understand, they go give us consent. They trust because there are black people that are, working here (FGD 4, Counsellors) The above quote demonstrates the way in which key stakeholder groups were, at times, represented in explicitly racialised terms, or grounded in racial categories which seemed to intersect with language and culture. The community was characterized as 'targeted' by researchers seeking to test their products, and as vulnerable 'victims' of research -with our respondents questioning the rationale for the selection of sites, and participating communities, and reporting similar questions by community members:
Why you targeting us? Is it because of we are poor, we don't have money, we don't have food? Why everything is done on us? We never, (you understand), even if there's an example they even mentioned, on television, anything, with crime or someone is sick it's always black (FGD 4, Counsellors) .
Why, why is the research done, [P2: on black people] in the area where there are black communities? And even the CAB members, some CAB members, still have that strong question like, 'why, ((taps table repeatedly)) are you coming here?" (FGD 2, CAB).
In contrast to these representations of (black) communities being deliberately 'targeted', other respondents argued that "it's not about black people or black communities, but it's about the areas where there is rate of unemployment…And reality is, the graveyard, they know every day somebody is dead" (FGD 2, CAB). Similarly, more epidemiologically-based explanations were also offered in this regard -"the researchers are coming to places where there is a high prevalence of i-HIV and AIDS. And we can't run away from the fact that it is where it is here in our townships" (FGD 1, CAB) .
It is likely that site-staff tasked with explaining that late-phase trials select high-risk participants (and that high-risk participants often experience many vulnerabilities) will encounter local representations that discredit or disqualify these explanations. Further, it is likely that these diverse characterizations of community selection (epidemiological versus exploitative) will compete with each other for dominance and, depending on which is given greater weight, potential participants may make quite different decisions about trials.
Community Advisory Boards: CAB representatives primarily represented themselves as 'a bridge between the site and community' and as powerful activists who are heroes in the "struggle for all" against HIV. They described themselves as people who "bring that truth because you want people to understand what is it [trials] about..". (FGD 2, CAB). However, some CAB members characterized the CAB as restricted, and having limited power to halt studies, or as seen by the community as "sell-outs":
"and now it's like 'oh you being bought, and the researchers are white, and now it's another [Wouter Basson]… 'you are still part of that rubbish!' [Someone: mm] 'You don't know these people.'… They will do this and this and this and that until you're all brainwashed …'you part of joining the research, and you part of doing, these trials, you don't know what these doctors do you don't so-so-you don't know what these white people do to people.' (FGD 2, CAB) These competing representations of CABs (as sell-outs versus heroes) contextualises why CAB members also described themselves as 'splitted' (FGD 1, CAB).
Even though CABs do not play a direct role in the consent process with actual participants, they play an indirect yet critical role in buttressing the credibility of the research(ers) and of information provided by site-staff about trials during engagement activities. They may also provide culturally-informed models of trial-related concepts. The diverse ways in which the CAB are characterized (heroes or sell-outs) may either enhance or undermine the perceived trustworthiness of trials, thereby mediating how information is interpreted or accepted by potential participants.
